Key result
Antiplatelet therapy, including aspirin, remains a mainstay of treatment for cardiovascular diseases by targeting platelet activation and arterial thrombus formation.
This review discusses the role of platelets in cardiovascular disease and the mechanisms of antiplatelet therapies, including aspirin and newer agents.
Answers are grounded in this paper and cite their sources.
Upholds antiplatelet therapy in CVD care; leaves open refinements with emerging agents.
Platelets play an important, life-saving role in hemostasis and blood clotting at sites of vascular injury. However, unwanted platelet activation and arterial thrombus formation are implicated in the onset of myocardial infarction, stroke and other cardiovascular diseases. Different mechanisms, such as vascular damage, the development of mural platelet thrombi as a response to injury and the biochemical effects of intraplatelet substances that are released in response to damage, may be involved. Thus, antiplatelet therapy has become a mainstay of treatment for these conditions and the benefit of antiplatelet drugs is documented across a wide spectrum of clinical conditions. Aspirin has been regarded as the prototype antiplatelet drug and is still the most widely used agent. Aspirin’s antiplatelet effect is directly due to irreversible inactivation of arachidonic metabolism and suppression of thromboxane A2 synthesis. However, platelet activation occurs via several pathways that do not rely on amplificatio...
No takes yet. Share an insight, caveat, or question.
Reiter et al. (2005) conducted a review in Cardiovascular diseases. Antiplatelet drugs was evaluated. Antiplatelet therapy, including aspirin, remains a mainstay of treatment for cardiovascular diseases by targeting platelet activation and arterial thrombus formation.
Synapse has enriched 10 related papers. Consider them for comparative context: